Company: XERI
Filing Date: 2025-10-02
Form Type: 10-K
Source: 0001477932-25-007303
Chunk: 151

Company: XERIANT, INC.
Filing Date: 2025-10-02
Form: 10-K
Item: Item 1A
Chunk 151
---
 ·the timing, results and capacity of our manufacturing operations; ·the success of existing or new competitive products or technologies; ·announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; ·establishment or termination of collaboration of our joint ventures or development programs; ·failure of discontinuation of any of our development programs; ·the success of our competitors’ new products entering the marketplace; ·regulatory or legal developments in the United States and other countries; ·developments or disputes concerning patent applications, issued patents or other proprietary rights; ·the recruitment or departure of key personnel; ·the level of expenses related to any of our product candidates or development programs; ·the results of our efforts to discover, develop, acquire or license additional products; ·actual or anticipated changes in estimates as to financial results or production and development timelines; ·announcement or expectation of additional financing efforts; ·sales of our common stock by us, our insiders or other stockholders; ·variations in our financial results or those of companies that are perceived similar to us; ·changes in estimates or recommendations by securities analysts, if any, that cover our stock; and ·general economic, industry and market conditions.

 24Table of Contents

Our directors and executive officers can exert significant control over our business and affairs and have actual or potential interests that may depart from those of investors in the subsequent financings.

The interests of our directors and officers may differ from the interests of our other stockholders, including purchasers of our securities, in future financings. As a result, based on their board seats and offices, such persons will have significant influence over and control all corporate actions requiring stockholder approval, irrespective of how the Company’s other stockholders, may vote, including the following actions:

 ●to elect or defeat the election of our directors;    ●to amend or prevent amendment of our Amended and Restated Articles of Incorporation or By-laws;    ●to effect or prevent a merger, sale of assets or other corporate transaction; and    ●to control the outcome of any other matter submitted to our stockholders for vote.

This concentration of ownership by itself may have the effect of impeding a merger, consolidation, takeover or other business consolidation, or discouraging a potential acquirer from making a tender offer for the Common Stock which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our